Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 13/20 | 1.00 |
| ▸ | DYRK2 | Q92630 | 13/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 12/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 11/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 9/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 7/20 | 1.00 |
| ▸ | CDK2 | P24941 | 7/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 7/20 | 1.00 |
| ▸ | CDK9 | P50750 | 7/20 | 1.00 |
| ▸ | FYN | P06241 | 3/20 | 0.64 |
| ▸ | PIM1 | P11309 | 4/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14373455 | 0.87 | DYRK1A (0.76) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL3033416 | 0.85 | DYRK1A (0.74) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL16216115 | 0.85 | DYRK1A (0.74) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL102417 | 0.85 | DYRK1A (0.74) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL14605702 | 0.85 | DYRK3 (0.74) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL13234217 | 0.85 | DYRK1A (1.00) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL102252 | 0.84 | DYRK1A (0.72) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL14605669 | 0.83 | DYRK1A (0.71) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL103269 | 0.83 | DYRK1A (0.71) | DYRK1ADYRK2DYRK1BDYRK3CDK5 | |
| SCHEMBL14852319 | 0.83 | FYN (0.74) | DYRK1ADYRK2DYRK1BDYRK3CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3812387-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3812387-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10875864-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10875864-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3409278-B1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3409278-B1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-2176266-A2 | SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES AS KINASE INHIBITORS, THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
| EP-2044071-A1 | OOXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007147646-A1 | OXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147646-A1 | OXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| WO-2007025540-A2 | SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES AS KINASE INHIBITORS, THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | CDK2, CDK1, MAP4K2 | DYRK1A 445/4885DYRK2 278/4885DYRK1B 371/4885 |
| US-10875864-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | PIM2, PIM1, PIM3 | DYRK1A 458/4885DYRK2 442/4885DYRK1B 473/4885 |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 171/4885DYRK2 122/4885DYRK1B 149/4885 |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 171/4885DYRK2 122/4885DYRK1B 149/4885 |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | DYRK1A 461/4885DYRK2 336/4885DYRK1B 451/4885 |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 171/4885DYRK2 122/4885DYRK1B 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.